Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
For Studies 2, 3 and 4, the primary efficacy parameters were mean percent change in body weight and the percentages of patients achieving greater than or equal to 5% weight loss from baseline to Week 68
The average amount of weight lost is similar to the amount of weeks you are on it (results vary per person)
Refractory disease risk was reduced by 40% at three months (RR 0.6, 95% CI 0.5200.692, p=0.0001)
Patients should aim to drink 91-125 ounces of fluid daily
What the Clinical Data Actually Shows The most definitive comparison comes from the SURMOUNT-5 trial, a direct head-to-head study published in the New England Journal of Medicine comparing tirzepatide 10 mg and 15 mg against semaglutide 2.4 mg in adults with obesity but without diabetes
US$ 27.56
US$ 20.85
US$ 21.42
